ABSTRACT BACKGROUND: We developed MTH1 inhibitors (MTH1i) TH588 and TH1579
INTRODUCTION
While targeting DNA repair, or the DNA damage response (DDR), as anti-cancer strategy has been a focus over many years [1] , the potential huge benefit it can offer is only now becoming apparent, for instance following the recent results obtained in first-line treatment with the PARP inhibitor (PARPi) olaparib in ovarian cancer [2] , especially homologous recombination defective (HRD) cancers [3, 4] . Targeting non-essential DNA repair proteins such as PARP1 is a priority and we and others earlier demonstrated that the non-essential DNA repair protein MTH1 is synthetic lethal with the cancer phenotype and developed potent MTH1 inhibitors (MTH1i) that have potent general anti-cancer activity while being well tolerated [5] [6] [7] [8] . Currently, the MTH1i karonudib (TH1579) is evaluated in clinical trials, making MTH1 amongst a very short list of DNA repair targets being evaluated in the clinic [9] .
The MTH1 protein is a poorly studied DNA repair enzyme and to date only described to prevent oxidized dNTPs, such as 8-oxodGTP and 2-OHdATP, from being incorporated into DNA [10, 11] . Other functions of MTH1 are unknown. Recently, it was demonstrated that potent MTH1i, structurally distinct from TH588 or TH1579, fail to kill cancer cells; challenging MTH1 as anti-cancer target altogether [12] [13] [14] . Here, we address the functions of MTH1 as well as the mechanism of action of TH588 and TH1579 along with other inhibitors to be able to explain the discrepancy between MTH1i. These results are important to increase our understanding on the mechanism of action of MTH1i currently being tested in clinical trials.
MATERIALS AND METHODS

Cell culture, Inhibitors, Immunofluorescence, Time-lapse microscopy
Cell lines were cultured at 37°C in 5% CO2 and in media supplemented with 10% FBS and TH588 [6] , TH1579 [15] , TH7238 and AZ cmpd #19, #21, #24 [12] were synthesized in house and prepared as previously reported, while other purchased CENP-E inhibitor (CENPEi; GSK923295, SelleckChem), Vincristine sulfate (Sigma Aldrich), Paclitaxel (Sigma Aldrich), Nocadozole (Sigma Aldrich), RO3306 (SelleckChem).
Immunofluorescence microscopy with suspension cells was performed as described previously [16] and the time-lapse was initiated after 30 min after treatment and images of GFP and brightfield channels were acquired every 10 min for 24 h. All other experiments are described in detail in supported materials and methods.
RESULTS
MTH1 is required for normal mitotic progression
We and others have previously shown that cancer cells die following MTH1 depletion in vitro and in vivo [6, 7, 15, 17] . When depleting MTH1 using different siRNA or shRNA in vitro or in vivo we observed cell division defects indicative of mitotic problems, such as formation of micronuclei or polynucleated cells ( Accurate cell division requires correct establishment of kinetochore-microtubule attachments, therefore, as a readout for correct attachments we next measured the inter-kinetochore distances in sister-chromatids, which was significantly reduced following MTH1 depletion ( Figure 1G -H), suggesting MTH1 contributes to the correct establishment of these attachments.
In accordance with the MTH1 siRNA results, although much more pronounced, U2OS cells treated with MTH1i TH588 and TH1579 showed an increased time in mitosis shortly after treatment, strongly associated with a delay in chromosome alignment, and their subsequent entry into G1 phase coincided with polynucleation ( Figure 2A -C, Supplementary   Figure 2A , Movies S1-S3). Interestingly, when we transfected immortalized BJ-hTERT and transformed BJ-RasV12 cells with H2B-GFP and followed their fate in mitosis after TH588 or TH1579 treatment using live cell imaging, we observed similar mitotic phenotypes in transformed BJ-RasV12, but not in BJ-hTERT cells ( Figure 2D -E). This is in line with our previous report of increased survival and lower levels of incorporated oxidised nucleotides, such as 8-oxodG, in non-transformed cells [6, 15] . Importantly, as cells were followed continuously by live-cell imaging, the difference between immortalized and Ras-transformed cells cannot simply be explained by Ras-transformed cells having a shorter cell cycle.
Furthermore, in accordance with MTH1 siRNA observations, we observed lagging chromosomes ( Figure 2B ) and a reduced inter-kinetochore distance in comparison to control or paclitaxel treated cells ( Figure 2F ). Thus, the mitotic phenotype observed after TH588 and TH1579 treatment was similar to the one observed following MTH1 depletion, although much more pronounced.
Interestingly we observed that a previously reported non-cytotoxic MTH1i, Astra Zeneca compound 19 (AZ19), was cytotoxic at higher concentrations (10-50 µM) and caused a congression defect similar to TH588 or TH1579 treatment or MTH1 depletion, and also resulted in a mitotic arrest and polynucleation ( Movies S7, S8). This further supports a role for MTH1 in mitotic progression, however given these compounds inhibits the enzymatic function of MTH1 at similar low nM concentrations, this suggests that the role of inhibitors disrupting the mitotic process is distinct from the enzymatic function of MTH1.
A novel role of MTH1 in microtubule dynamics
Since microtubule dynamics are crucial for accurate mitotic progression [18] and MTH1 depletion interfered with correct kinetochore-microtubule attachments, and caused mitotic delays, lagging chromosomes and polynucleation, we hypothesized that MTH1 plays a role in microtubule dynamics. To test this, microtubule plus end growth rates were determined by tracking EB3-GFP protein in living HCT116 cells. 48h siRNA knockdown of MTH1 did not influence microtubule polymerization rate ( Figure 3A ), but a prolonged MTH1 siRNA treatment (96 h) of HCT116 cells showed a reduction of the microtubule polymerization rate ( Figure 3B , Movie S4). Furthermore, by using fluorescence recovery after photobleaching (FRAP) in U2OS cells expressing mCherry-tagged alpha-tubulin, we could show that tubulin mobility was increased in mitotic cells after MTH1 siRNA depletion which is in agreement with the observed reduction in microtubule polymerization (Figure 3C -E; Supplementary Figure 2D -E). These data suggest a role of MTH1 in tubulin function. Next, we performed pull down experiments using U2OS cells expressing MTH1-GFP or, a catalytically-dead variant of MTH1, GFP-E56A mutated MTH1. Interestingly, alpha-tubulin was found to be bound to MTH1-GFP and significantly less bound to the GFP-E56A mutated MTH1 ( Figure   3F -G). The MTH1 and alpha-tubulin interaction was further confirmed using a previously described F3H interaction assay [19, 20] . In brief, a high-affinity GFP binding nanobody (GBP) is coupled to the Lac repressor (LacI) and stably expressed in U2OS F3H cells, which harbor a stably integrated lac operator array (LacO). The GBP-LacI protein binds to the LacO and recruits any GFP-fusion protein that is co-expressed to this LacO region ( Figure 3H ).
Expression of MTH1-GFP in these cells resulted in nucleation of alpha-Tubulin filaments spreading from the MTH1-GFP bound LacO region ( Figure 3I ). This indicates that MTH1 and tubulin interact in cells and that MTH1 potentially can even initiate microtubule nucleation. Taken together, these data show that MTH1 interacts with alpha-tubulin and establishes a role for MTH1 in microtubule dynamics, with MTH1 being required for normal mitotic progression.
TH588 or TH1579 affect tubulin and microtubule dynamics
Previously, TH588 has been reported to inhibit tubulin polymerisation in vitro and this was suggested to be responsible for cell killing activity [13] . We can confirm that TH588, and TH1579, inhibit polymerisation of tubulin in vitro in a concentration-dependent manner ( Figure 3A) . In comparison, in silico docking to the colchicine binding pocket suggested TH588 to interact weaker than TH1579 but stronger compared to AZ19 ( Figure 4C ). To understand how relevant these direct effects on microtubules polymerisation in vitro were at therapeutic concentrations in an in vivo situation, we subsequently measured microtubule mass and dynamics in cells. Firstly we used a cell-based assay monitoring whole cell microtubule mass and treated HCT116 cells with TH1579, TH588, Paclitaxel, Vincristine or a CENP-Ei, at concentrations 2-fold higher than the EC 50 value obtained from cell viability assays in BJ Ras cells. As expected, paclitaxel significantly enhanced the mass of microtubules and vincristine reduced it. Surprisingly, the CENP-Ei significantly enhance microtubule mass ( Figure 4D, Supplementary Figure 3B ). MTH1i TH588 did not significantly change the whole microtubule mass, but TH1579 treatment significantly reduced the microtubule mass ( Figure 4D, Supplementary Figure 3B ).
We next assayed microtubule dynamics by measuring microtubule plus end assembly rates in live HCT116 cells by monitoring EB3-GFP assembly. We observed a dose-dependent reduction of microtubule polymerisation rates following 1.5 hours treatment with TH588 and TH1579 ( Figure 4E-F) . Next, we used U2OS cells stably expressing H2B-GFP and Cherry- together, these data demonstrate that mitotic arrest leads to increased ROS levels, and in-turn, this is required for the increase in genomic oxidised nucleotides.
Inhibition of microtubule polymerisation dynamics synergizes with inhibition of MTH1-dependent 8-oxodGTPase activity
Our revised mechanism of action for TH588 and TH1579 suggests our compounds arrest cells in mitosis by perturbing microtubule dynamics, both directly and indirectly, resulting in an increase in ROS and incorporation of oxidised nucleotides into DNA.
Previously, repair/replication synthesis has been reported to occur in mitosis [24] and here we suggest that this mitotic repair/replication synthesis is responsible for incorporation of oxidized dNTPs into DNA (Rudd et al., submitted). Hence, MTH1 may play a pivotal role in preventing oxidized dNTP incorporation during mitosis, which may be lethal.
To test if incorporation of 8-oxodGTP into DNA is toxic and if MTH1 is important in preventing such lethal incorporation, we injected 8-oxodGTP into zebrafish embryos followed by treatment with TH588, or other potent MTH1i that fail to kill cancer cells [12] .
Interestingly, the non-cytotoxic MTH1i are equipotent to TH588 in killing zebrafish embryos 
DISCUSSION
Here, we show that MTH1 has a previously uncharacterized function in mitotic progression. Following MTH1 siRNA treatment we observe a mitotic defect that is manifested by an increased time in mitosis and a decreased inter-kinetochore distance, which is a likely consequence of disrupted microtubules being unable to pull chromosomes apart. To further substantiate the role of MTH1 in mitosis, we observe MTH1 and tubulin interactions in cells, with a potential role for MTH1 to initiate microtubule nucleation.
It is established that cells accumulate ROS when arrested in mitosis [22, 23] . In line with this, we report mitotic poisons and inhibitors increases ROS, as well as TH588 and TH1579. We suggest MTH1 enzymatic activity is required under these stressed conditions to prevent incorporation of 8-oxodGTP into DNA. In support of this, no elevated levels of 8-oxodG in DNA is observed by paclitaxel, vincristine or CENPEi in spite of ROS being produced. In contrast, TH588 and TH1579 specifically elevate incorporation of 8-oxodGTP into DNA, by inhibiting MTH1-dependent 8-oxodGTPase activity. Hence, it appears that arrest in mitosis is required for ROS accumulation while concurrent MTH1i results in incorporation of 8-oxodG into DNA. We demonstrate that decreasing the time spent in mitosis using MAD2 siRNA prevented not only 8-oxodG in DNA but also cellular toxicity after TH588 or TH1579 treatment. We thus suggest that the improved survival in response to TH588 and TH1579 treatment in cells, where the spindle assembly checkpoint is disturbed, can be explained by less time spent in mitosis, ultimately resulting in lower levels of ROS generation and reduced accumulation of toxic 8-oxodG in DNA. Previously, both we and others have demonstrated that cell death caused by TH588 treatment is associated with ROS formation, supporting this hypothesis [25, 26] . Hence, MTH1i of 8-oxodGTPase only becomes relevant in presence of ROS in mitotically arrested cells.
To test if mitotic arrest and 8-oxodGTPase inhibition are both relevant for MTH1i, we combined the MTH1i AZ19 at doses that only inhibits MTH1 enzymatic activity with paclitaxel or CENPEi. The lack of 8-oxodG detection in DNA after AZ19 treatment alone is likely due to the fact that no mitotic arrest is induced with these sub-lethal doses of AZ19.
Conversely, ROS induced by paclitaxel or CENPEi do not lead to 8-oxodG in DNA because of functional MTH1 activity sanitizing oxidized nucleotides. Cytotoxicity and 8-oxodG in DNA is only observed when ROS is induced by paclitaxel or CENPEi and MTH1 inhibited by AZ19. Our conclusion is that there is a dual mechanism of action to kill cancer cells, by (1) arrest in mitosis and (2) Hence, this suggests that the underlying ROS levels in cancer cells is overall too low to be toxic to cells upon MTH1i and that additional mitotic arrest to elevate ROS levels is necessary.
Cells treated with TH588, TH1579, AZ19 and also other chemically distinct MTH1i (data not shown) show similar phenotypes as observed following MTH1 siRNA treatment when it comes to congression defect, decreasing microtubule polymerisation rates, tubulin mobility, decreased inter-kinetochore distance, arrest in mitosis and generation of polynucleated cells.
Importantly, the TH588 and TH1579 compounds show more pronounced mitotic arrest and effect on microtubule polymerisation as compared to AZ19, other MTH1i or MTH1 siRNA.
We propose that this is likely explained by the direct effect on tubulin polymerisation shared by the TH588 and TH1579 compounds, which is not observed with AZ19. This is supported by TH588 and TH1579 being able to inhibit tubulin polymerisation in vitro and also affecting tubulin mobility in cells more profoundly. Since TH1579 is likely binding to the colchicine site on tubulin one would expect that the effects of TH1579 would be masked during treatments with colchicine. In contrast to this, TH1579 and colchicine potently synergize suggesting they do not share the same mechanism of action.
In conclusion, here we demonstrate that the MTH1 protein is mediating microtubule polymerisation rates required for progression of mitosis in cancer cells, which is likely by binding tubulin directly. Furthermore, some potent MTH1i break the MTH1-tubulin interaction while others do not. TH588 and TH1579 have additional effects on tubulin contributing to a stronger mitotic arrest from that observed with AZ19 or MTH1 siRNA alone. Active MTH1i work through a dual mechanism of action by inhibition of mitosis as well as inhibition of 8-oxodGTPase activity. Values are from 3 independent experiments (mean±SD, ns: non significant, *: p<0.05, ****:
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p<0.0001, One-way ANOVA). 
